Assessment of Fraction of Exhaled Nitric Oxide and Soluble Receptor for Advanced Glycation End Products Biomarkers for Jordanian Asthmatic Children

PURPOSE: Fraction of exhaled nitric oxide (FeNO) and soluble advanced glycation end-product receptor (sRAGE) are proposed as biomarkers of asthma, therefore we sought to assess their use in asthmatic children of Jordan.

PATIENTS AND METHODS: We conducted a case-control study at The University of Jordan Hospital.

A total of 141 asthmatic children followed by respiratory pediatricians and 118 healthy children aged 4–18 years were recruited.

FeNO was measured by NObreath device and serum sRAGE by ELISA that detect endogenously soluble isoform (esRAGE) and total soluble RAGE (sRAGE).

RESULTS: sRAGE in asthmatic was half of the control (p <0.001).

In addition, ratio of esRAGE/sRAGE was two-fold higher in asthmatic (p = <0.001).

Neither FeNO nor esRAGE levels were significantly different between groups.

FeNO and asthma control test (ACT) score were negatively correlated corrected for age and body mass index (BMI), (r = −0.180, p= 0.034).

For the uncontrolled asthma group, esRAGE/sRAGE negatively correlated with ACT score (r = −.329, p = 0.038).

Receiver operating curve (ROC) analysis revealed significant predictive value (PV) for sRAGE and esRAGE/sRAGE in asthma detection with area under the curve (AUC) of (0.751 ± 0.031) and (0.711±.033), consequently.

However, no biomarker had a significant PV for lack of control.

CONCLUSION: The current study supports utilizing sRAGE as a marker for asthma and present a potential therapeutic target.

However, our results indicate that both FeNO and sRAGE have a limited role in the management of asthmatic children or assessment of asthma control.